Trials / Completed
CompletedNCT01302015
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease
Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- R-Bio · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Buerger's disease.
Detailed description
Buerger's disease, also known as thromboangiitis obliterans, is a rare disorder that, in most cases, affects young or middle-aged male cigarette smokers. It is characterized by narrowing or blockage (occlusion) of the veins and arteries of the extremities, resulting in reduced blood flow to these areas (peripheral vascular disease). The exact cause of Buerger's disease is not known; however, most affected individuals are heavy tobacco users. This drug is an autologous cell treatment for necrosis in the legs of patients with Beurger's diseases to improve symptoms through vascular regeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RNL-Vascostem® |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2011-02-23
- Last updated
- 2019-06-05
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01302015. Inclusion in this directory is not an endorsement.